Matching articles for "Baxdela"
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • April 17, 2023; (Issue 1674)
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • January 25, 2021; (Issue 1616)
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
In Brief: More Fluoroquinolone Warnings
The Medical Letter on Drugs and Therapeutics • August 13, 2018; (Issue 1553)
The FDA has required changes in the labeling of all systemic fluoroquinolone antibiotics to strengthen warnings about the risk of severe hypoglycemia and mental health effects associated with their use.1An FDA...
The FDA has required changes in the labeling of all systemic fluoroquinolone antibiotics to strengthen warnings about the risk of severe hypoglycemia and mental health effects associated with their use.1
An FDA review identified 67 cases of hypoglycemic coma associated with fluoroquinolone use, 22 of which resulted in death or disability. Most cases occurred in patients with risk factors such as diabetes (especially those taking a sulfonylurea), older age, or renal insufficiency.1 In observational studies in older adults and patients with diabetes, fluoroquinolones have been associated with increased risks of hypo- and hyperglycemia.2,3 Patients taking a fluoroquinolone (especially those with risk factors) should be counseled about the symptoms of hypoglycemia and monitored for blood glucose disturbances. The drug should be stopped if dysglycemia occurs.
The labels of all systemic fluoroquinolones will now include warnings about delirium, agitation, nervousness, and disturbances in attention, memory, and orientation. These effects can occur after a single fluoroquinolone dose; the drug should be stopped if such effects occur. Systemic fluoroquinolones can also cause persistent or permanent peripheral neuropathy,4 and their use has been associated with an increased risk of pseudotumor cerebri syndrome.5
Other serious adverse effects associated with use of systemic fluoroquinolones include tendinitis and tendon rupture, exacerbation of myasthenia gravis, Clostridium difficile infection, and (except for delafloxacin [Baxdela]) QT-interval prolongation and torsades de pointes. The FDA recommends avoiding use of fluoroquinolones in patients with uncomplicated urinary tract infection, acute sinusitis, or acute exacerbation of chronic bronchitis, except when no alternative treatment option is available.6
Additional Content Available Online: Comparison Table: Some Systemic Fluoroquinolones
Download complete U.S. English article
An FDA review identified 67 cases of hypoglycemic coma associated with fluoroquinolone use, 22 of which resulted in death or disability. Most cases occurred in patients with risk factors such as diabetes (especially those taking a sulfonylurea), older age, or renal insufficiency.1 In observational studies in older adults and patients with diabetes, fluoroquinolones have been associated with increased risks of hypo- and hyperglycemia.2,3 Patients taking a fluoroquinolone (especially those with risk factors) should be counseled about the symptoms of hypoglycemia and monitored for blood glucose disturbances. The drug should be stopped if dysglycemia occurs.
The labels of all systemic fluoroquinolones will now include warnings about delirium, agitation, nervousness, and disturbances in attention, memory, and orientation. These effects can occur after a single fluoroquinolone dose; the drug should be stopped if such effects occur. Systemic fluoroquinolones can also cause persistent or permanent peripheral neuropathy,4 and their use has been associated with an increased risk of pseudotumor cerebri syndrome.5
Other serious adverse effects associated with use of systemic fluoroquinolones include tendinitis and tendon rupture, exacerbation of myasthenia gravis, Clostridium difficile infection, and (except for delafloxacin [Baxdela]) QT-interval prolongation and torsades de pointes. The FDA recommends avoiding use of fluoroquinolones in patients with uncomplicated urinary tract infection, acute sinusitis, or acute exacerbation of chronic bronchitis, except when no alternative treatment option is available.6
Additional Content Available Online: Comparison Table: Some Systemic Fluoroquinolones
- FDA. July 10, 2018. Available at: www.fda.gov. Accessed August 2, 2018.
- LY Park-Wyllie et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352.
- HW Chou et al. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013; 57:971.
- In brief: Fluoroquinolones and peripheral neuropathy. Med Lett Drugs Ther 2013; 55:89.
- M Sodhi et al. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: nested case-control study. Neurology 2017; 89:792.
- Alternatives to fluoroquinolones. Med Lett Drugs Ther 2016; 58:75.
Download complete U.S. English article
Comparison Table: Some Systemic Fluoroquinolones (online only)
The Medical Letter on Drugs and Therapeutics • March 26, 2018; (Issue 1543)
...
View the Comparison Table: Some Systemic Fluoroquinolones (online only)
Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections (online only)
The Medical Letter on Drugs and Therapeutics • March 26, 2018; (Issue 1543)
...
View the Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections
Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic
The Medical Letter on Drugs and Therapeutics • March 26, 2018; (Issue 1543)
The FDA has approved delafloxacin (Baxdela –
Melinta), an anionic fluoroquinolone antibiotic, for oral
and parenteral treatment of adults with acute bacterial
skin and skin structure infections (ABSSSIs),...
The FDA has approved delafloxacin (Baxdela –
Melinta), an anionic fluoroquinolone antibiotic, for oral
and parenteral treatment of adults with acute bacterial
skin and skin structure infections (ABSSSIs), including
those caused by methicillin-resistant Staphylococcus
aureus (MRSA). It is the first fluoroquinolone to be
approved for treatment of MRSA.